Back

Amiodarone therapy and risk of primary lung cancer; insights from a real-life contemporary population study

29 August 2022 (14:15 - 15:00)
Organised by:
Congress Presentation Part of: Novel medication strategies in atrial fibrillation Antiarrhythmic Drug Treatment ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Gal Tsaban

Mayo Clinic, Rochester (United States of America)

5 More presentations in this session

Presentation thumbnail
Dronedarone as early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET4 criteria
Professor J. Piccini (Durham, US)
Abstract Slides
Presentation thumbnail
Amiodarone and Lung Toxicity in a real-life contemporary population
Doctor G. Tsaban (Rochester, US)
Abstract Slides
Presentation thumbnail
Chronic amiodarone therapy and mortality among atrial fibrillation patients; insights from a real-life contemporary population
Doctor G. Tsaban (Rochester, US)
Abstract Slides
Presentation thumbnail
Alleviation of AF related symptoms following acute conversion of recent-onset, symptomatic atrial fibrillation to sinus rhythm with flecainide acetate oral inhalation solution
Professor J. Camm (London, GB)
Abstract Slides
Presentation thumbnail
Predictors of successful cardioversion of recent-onset atrial fibrillation to sinus rhythm with orally inhaled flecainide
Doctor H. Crijns (Maastricht, NL)
Abstract Slides

Access the full session

Session thumbnail
Novel medication strategies in atrial fibrillation

The Event

Event poster

ESC Congress 2022

29 August 2022 14:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources